Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of amikacin in cystic fibrosis patients with nontuberculous mycobacterial infections

Trial Profile

Phase II study of amikacin in cystic fibrosis patients with nontuberculous mycobacterial infections

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Nontuberculous mycobacterium infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2021 According to an Matinas BioPharma Media release, the company expects to initiate this study by the first quarter of 2023, following required longer-term preclinical toxicology studies to be conducted during 2022.
    • 10 May 2021 According to an Matinas BioPharma Media release, the company expects to initiate this trial in 2022.
    • 20 Dec 2020 According to a Matinas BioPharma media release, the Cystic Fibrosis Foundation (CFF) has indicated to the company a willingness to consider a request for monetary support for the continuation of clinical studies, including dose determination and Phase 2 efficacy studies in CF patients suffering from NTM lung disease.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top